49 Wealth Management’s GT Biopharma GTBP Stock Holding History

49 Wealth Management’s Portfolio GTBP Stock Details GTBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$31.3K	Buy	+64,000	New	+$26K	0.01%	189

Other funds holding GTBP

Everhart Financial Group Dublin, Ohio $1.56B AUM 34.29% 1-Year Est. Return

Arax Advisory Partners Denver, Colorado $15.1B AUM 27.93% 1-Year Est. Return

Opal Wealth Advisors Jericho, New York $463M AUM 20.47% 1-Year Est. Return

SeaCrest Wealth Management Purchase, New York $903M AUM 47.26% 1-Year Est. Return

Kitching Partners Conshohocken, Pennsylvania $116M AUM 16.12% 1-Year Est. Return

PNC Financial Services Group

PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Private Wealth Management Group Princeton, New Jersey $431M AUM 20.62% 1-Year Est. Return

Sagespring Wealth Partners Franklin, Tennessee $6.51B AUM 25.32% 1-Year Est. Return

Tempus Wealth Planning Irvine, California $511M AUM 28.39% 1-Year Est. Return

49 Wealth Management's GTBP Position: Q2 2026 in Review

49 Wealth Management opened a new position in GT Biopharma (GTBP) in Q2 2026: 64,000 shares worth $31.3K. The stake represents 0.01% of the portfolio and ranks #189 among its holdings.

28 funds tracked by Wall St. Rank hold GTBP as of Q2 2026.

49 Wealth Management held 64,000 shares of GT Biopharma worth $31.3K as of Q2 2026.
GT Biopharma was a new 49 Wealth Management position in Q2 2026.
GT Biopharma made up 0.01% of 49 Wealth Management's portfolio in Q2 2026, its #189 holding.
28 funds tracked by Wall St. Rank held GT Biopharma as of Q2 2026.

Based on 49 Wealth Management's 13F filing for Q2 2026, filed 10 Aug 2026.